Elevate your lab and patient outcomes with local comprehensive genomic profiling

Comprehensive genomic profiling (CGP) by next-generation sequencing (NGS) is a powerful clinical tool for assessing a patient’s tumor mutational profile, identifying the most appropriate treatment strategy and individualizing each patient’s cancer care.

While genomic testing has historically been limited to a handful of centralized commercial laboratories — thus reducing patient access and increasing turnaround times for clinical results — the PGDx elio™ tissue complete test offers an FDA-cleared solution, including automated bioinformatics analysis for tumor profiling in-house.

At the 2022 Cancer Genomics Consortium, Ravindra Kolhe, MD, PhD, FACP, of Augusta University, discussed the critical role of CGP in precision oncology, in-house versus send-out testing approaches, challenges in implementation, the path to reimbursement and more.

Watch Webinar
Ravindra Kolhe, MD, PhD, FCAP
Professor of Pathology and Interim Chair, Department of Pathology, Medical College of Georgia, Augusta University

Currently, Dr. Kolhe divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory.

Sign up to watch webinar
By submitting this form, you affirm that you have read and understand the Privacy Policy and Terms of Use.

Educational tools to facilitate local
comprehensive genomic profiling